Skip to main content
Clinical Trials/NCT03035656
NCT03035656UnknownPhase 4

Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion

Horizon Health Network0 sites228 target enrollmentStarted: March 1, 2019Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Enrollment
228
Primary Endpoint
Change in Pain

Study Overview

Brief Summary

The following is a double blinded, randomized controlled clinical trial to test the hypothesis that a single epidural injection of Ropivaciane® intra operatively will:1) Single intra-operative epidural injection of Ropivaciane® will result in decreased postoperative pain and opioid use in both minimally invasive (MIS) and open lumbar fusion patients; 2) Decreased postoperative pain will lead to improved clinical outcomes; and 3) Elucidate if there are differences in pain management between MIS and open surgical procedures. The proposed study will add novel information to current knowledge by 1) exploring of the effects of intra-operative single epidural injection analgesic on patients receiving MIS compared to open surgery, and 2) investigate potential immediate and short-term functional improvements gained from intra-operative single injection of Ropivaciane®.

Detailed Description

This double blinded, randomized clinical trial will test hypotheses by administering a single epidural injection prior to wound closure of either Ropivaciane® or saline.All pre-surgical activities and anesthesia will proceed as usual, with the addition of a single epidural injection immediately prior to wound closure 2 levels, or 10cm above the operated spinal level. Experimental groups will receive 0.2% Ropivaciane® (10 ml; dose shown to be effective without transient weakness), 9 and the control group will receive 0.9% saline solution (10 ml). Accurate placement into the space will be verified by the injection of contrast medium (iohexol, 180 mgl/ml) under fluoroscopic guidance. Epidural solutions will be prepared prior to surgery by pharmacy and coded; surgeons will administer according to the patient's code maintaining the double-blind procedure. It is important to note that treatment as usual differs between open and MIS cohorts. The question of interest is whether the addition of the epidural analgesic to current practices for each surgery type results in increased positive outcomes, whether this is due to synergistic effects or not. Following operative treatment, Foley Urinary catheter will be removed 24 hours post-operatively, unless otherwise clinically indicated.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description

Randomization of arms are conducted by the pharmacy department, and drug or saline preparation are prepared by the pharmacy department.

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Consenting participants undergoing elective 1-2 level lumbar fusion through the Canada East Spine Centre

Exclusion Criteria

  • History of severe respiratory, renal or hepatic disease
  • Previous spine surgery
  • Known allergy to local anaesthesia
  • Those who experience dural tear during operative procedure

Arms & Interventions

Experimental

Experimental

Administration of epidural Ropivaciane

Intervention: Ropivacaine (Drug)

Control

Placebo Comparator

Administration of saline

Intervention: Saline (Other)

Outcomes

Primary Outcomes

Change in Pain

Time Frame: Administered 6 weeks pre-operatively, 2, 4, 8, 12, 24 and 48 hours post-operatively, 6 months post operatively, and 12 months post operatively

Back and leg pain measured using the validated Numeric Rating Scales (NRS) for back and leg pain.

Secondary Outcomes

  • Change in Medication Use(Investigated 2, 4, 8, 12, 24 and 48 hours post-operatively.)
  • Change in General Health(Administered 6 weeks pre-operatively, 6 and 12 months post-operatively)
  • Change in Disability(Administered 6 weeks pre-operatively, 6 and 12 months post-operatively)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. neil Manson

Principal Investigator

Horizon Health Network

Similar Trials

Effects of Intra-Operative Ropivaciane... | Clinical Trial